We are live on
!
Find out more
DA
Dillon & Associates Portfolio holdings
AUM
$726M
1-Year Est. Return
18.59%
This Fund
S&P 500
This Quarter
Est. Return
+1.67%
1 Year Est. Return
+18.59%
3 Year Est. Return
+92.03%
5 Year Est. Return
+130.73%
10 Year Est. Return
+511.58%
AUM
$218M
AUM Growth
+$2.14M
(+0.99%)
Cap. Flow
-$446K
Cap. Flow
% of AUM
-0.2%
Top 10 Holdings %
Top 10 Hldgs %
43.02%
Holding
70
New
1
Increased
21
Reduced
36
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starbucks
SBUX
|
+$552K |
| 2 |
Danaher
DHR
|
+$379K |
| 3 |
CVS Health
CVS
|
+$293K |
| 4 |
O'Reilly Automotive
ORLY
|
+$246K |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$222K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Beer
SAM
|
+$809K |
| 2 |
SRCL
Stericycle Inc
SRCL
|
+$523K |
| 3 |
Novartis
NVS
|
+$301K |
| 4 |
SLB Ltd
SLB
|
+$236K |
| 5 |
Qualcomm
QCOM
|
+$223K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.17% |
| 2 | Technology | 17.37% |
| 3 | Consumer Staples | 16.72% |
| 4 | Consumer Discretionary | 9.72% |
| 5 | Industrials | 9.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Amgen
AMGN
$208B
| $568K | 0.26% |
3,739
| – | – |
|
52
Core Laboratories
CLB
$488M
| $539K | 0.25% |
4,350
| – | – |
|
|
53
CVS Health
CVS
$133B
| $511K | 0.23% |
5,325
+2,940
| +123% | +$293K |
|
54
Cisco
CSCO
$457B
| $439K | 0.2% |
15,123
| – | – |
|
55
Genuine Parts
GPC
$17.1B
| $432K | 0.2% |
4,280
-175
| -4% | -$17K |
|
56
Biogen
BIIB
$30B
| $407K | 0.19% |
1,680
+245
| +17% | +$64.6K |
|
|
ESRX
57
DELISTED
Express Scripts Holding Company
ESRX
| $405K | 0.19% |
5,325
+580
| +12% | +$42.6K |
|
58
Microsoft
MSFT
$3.45T
| $401K | 0.18% |
7,861
-160
| -2% | -$8.31K |
|
59
Kraft Heinz
KHC
$30.7B
| $328K | 0.15% |
3,725
| – | – |
|
60
Eaton
ETN
$161B
| $285K | 0.13% |
4,756
-600
| -11% | -$36.9K |
|
61
Target
TGT
$65.6B
| $273K | 0.13% |
3,900
-250
| -6% | -$18.6K |
|
62
AT&T
T
$159B
| $247K | 0.11% |
7,598
+264
| +4% | +$7.86K |
|
63
IBM
IBM
$211B
| $243K | 0.11% |
1,674
| – | – |
|
64
Verizon
VZ
$195B
| $241K | 0.11% |
4,305
| – | – |
|
65
Chevron
CVX
$392B
| $234K | 0.11% |
2,233
| – | – |
|
66
Emerson Electric
EMR
$83.9B
| $232K | 0.11% |
4,457
-600
| -12% | -$31.9K |
|
67
Gilead Sciences
GILD
$162B
| $230K | 0.11% |
2,775
-250
| -8% | -$22.2K |
|
68
Altria Group
MO
$114B
| $228K | 0.1% |
3,307
-50
| -1% | -$3.2K |
|
|
CMA
69
DELISTED
Comerica
CMA
| $211K | 0.1% |
+5,157
| New | +$220K |
|
|
GCVRZ
70
DELISTED
Sanofi Contingent Value Rights
GCVRZ
| $3K | ﹤0.01% |
10,660
| – | – |
|
Similar funds
TC
F
SDH
SCM
MWP
FAN
TFHU
AGAM
Dillon & Associates's Q2 2016 Portfolio in Review
As of Q2 2016, Dillon & Associates held 70 positions worth $218M, up 0.99% from $216M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Trading was light in Q2 2016: portfolio turnover was 1.4%. Dillon & Associates opened 1 new position and made no exits, leaving the 70-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 23% a quarter earlier, followed by Technology and Consumer Staples.
- Dillon & Associates's largest Q2 2016 buy was Comerica: 5,157 shares worth $211K.
- Dillon & Associates added most to Starbucks in Q2 2016, an estimated $552K increase.
- Dillon & Associates's biggest Q2 2016 reduction was Boston Beer, cutting an estimated $809K.
- Dillon & Associates's ten largest holdings make up 43% of its $218M portfolio in Q2 2016.
- Dillon & Associates opened 1 new position and closed 0 in Q2 2016.
- Dillon & Associates's portfolio value rose 0.99% quarter-over-quarter to $218M.
Based on Dillon & Associates's 13F filing for Q2 2016, filed 12 Aug 2016.